Evidence map›Paper›PMID 41551843›Full record

ArticleClinical kidney journal2026

Cardiac impact of dapagliflozin in advanced chronic kidney disease: rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies.

Micky Karsten, Sunil V Badve, Ron T Gansevoort, Stefan P Berger, Hiddo J L Heerspink, Alferso C Abrahams, Laurent Billot, Rianne H A C M Bon, Mariëlle A C J Gelens, Dean Guinness and 17 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05374291. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05374291 phase3enrolling by invitation

A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease

Ran2022Enrolled1,750Registered outcomes12Posted comparisons0ConditionsDeath, Heart Failure, Kidney Disease, Chronic, Kidney FailureArmsDapagliflozin 10 mg/day (oral), Placebo
PMID 30990260PMID 34619108PMID 34272327PMID 40053493PMID 33213078other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Micky KarstenDepartment of Nephrology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Sunil V BadveThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Ron T GansevoortDepartment of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Stefan P BergerDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Alferso C AbrahamsDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
Laurent BillotThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Rianne H A C M BonDepartment of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Mariëlle A C J GelensDivision of Nephrology, Department Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Dean GuinnessKidney Health Consumer Panel, The George Institute of Global Health, University of New South Wales, Sydney, Australia.
Christian Hamilton-CraigThe University of Queensland, Faculty of Medicine and Centre for Advanced Imaging, Brisbane, Australia.
Loek van HeerebeekDepartment of Cardiology, OLVG, Amsterdam, The Netherlands.
Marc H HemmelderDepartment of Internal Medicine, division of Nephrology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Lauren HoustonThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Rebecca KozorThe University of Sydney, Sydney, Australia.
Dirk R J KuypersDepartment of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
Helen MonaghanThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Bruce NealThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Brendon L NeuenThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
James OttonUniversity of New South Wales, Sydney, Australia.
Vlado PerkovicUniversity of New South Wales, Sydney, Australia.
Adil RajwaniRoyal Perth Hospital, Department of Cardiology, Perth, Australia.
Angela Y WangDepartment of Renal Medicine, Singapore General Hospital, Singapore, Singapore.
Marc G VervloetDepartment of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Clare ArnottThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Lily JakuljDepartment of Nephrology, Amsterdam University Medical Center, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-8678-682X
Renal Lifecycle Trial Cardiac Imaging Sub-studies Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with chronic kidney disease (CKD) are frequently hospitalized for heart failure. Sodium-glucose co-transporter 2 (SGLT2)-inhibitors improve cardiorenal outcomes in CKD and heart failure, at least in estimated glomerular filtration rate (eGFR) ranges 20-60 ml/min/1.73 m Methods: In the Renal Lifecycle Trial, patients with advanced CKD (eGFR ≤25 ml/min/1.73 m Conclusions: The Renal Lifecycle Trial cardiac imaging sub-studies will generate novel data on the effects of SGLT2-inhibition on cardiac structure and function in a population with advanced CKD, in whom SGLT2-inhibitor induced cardiovascular protection remains to be established. Clinical Trial Registration: The Renal Lifecycle Trial and its sub-studies are registered at ClinicalTrials.gov under registration number NCT05374291.

Indexed as

cardiac magnetic resonance imagingchronic kidney diseasedapagliflozinechocardiographysodium-glucose co-transporter 2 inhibitors

Identifiers

PMID41551843
PMCPMC12805250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.